Observation of clinical efficacy of Ying-Pi No.1 hand mask cream in the treatment of scleroderma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100005418

Enrollment

Unknown

Registered

2021-12-17

Start date

2019-10-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

scleroderma

Interventions

Test group:MTX+ Alprostadil injection + Guipiperate maleate injection + Ying-Pi No.1 hand mask cream for external application

Control group:MTX+ Alprostadil injection + Guipiperate maleate injection

Eligibility

Sex/Gender

All

Age

28 Years to 78 Years

Inclusion criteria

Inclusion criteria: Patients who met the SSc classification diagnostic criteria of The American College of Rheumatology (ACR) in 2013(score 9 points) and whose skin involvement was in the stage of swelling and sclerosis.

Exclusion criteria

Exclusion criteria: Patients with important organ involvement, such as pulmonary interstitial disease, pulmonary hypertension, pericardial effusion or hypertrophic inflammatory myopathy, need more than 0.5mg/kg/day glucocorticoid treatment; Patients with renal crisis; Patients with arteriovenous thrombosis and diabetes-related gangrene; Patients with SSC-related gangrene infection; Local skin is extensively damaged and cannot be applied externally.

Design outcomes

Primary

Measure	Time frame
mRSS;Number of loops Input branch diameter output branch diameter top diameter of loop length of loop malformation ratio number of shallow corrugated nipples;	—

Countries

China

Contacts

Public ContactXu Liping

yuqian920920@126.com13819116384

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026